Tazeen Ahmad analyst BAML

Currently out of the existing stock ratings of Tazeen Ahmad, 308 are a BUY (69.53%), 97 are a HOLD (21.9%), 38 are a SELL (8.58%).

Tazeen Ahmad

Work Performance Price Targets & Ratings Chart

Analyst Tazeen Ahmad, currently employed at BAML, has had 59.16% of price targets met with an average potential upside of 30.75%, reached in 176 days on average.

Tazeen Ahmad has documented 877 price targets and ratings displayed on 67 stocks. The coverage is on Healthcare, Industrials sectors.

Most recent stock forecast was given on REGN, Regeneron Pharmaceuticals at 02-Nov-2026.

Wall Street Analyst Tazeen Ahmad

Analyst best performing recommendations are on SRZN (SURROZEN).
The best stock recommendation documented was for SRZN (SURROZEN) on 11/17/2022. The price target of $15 was fulfilled within 1 day with a profit of $1.65 (9.91%), with a performance score of 99.1.

Average potential price target upside

ACAD ACADIA Pharmaceuticals ALNY Alnylam Pharmaceuticals BNTX BioNTech SE FOLD Amicus Therapeutics FULC Fulcrum Therapeutics GRTX Galera Therapeutics GWPH GW Pharmaceuticals plc INCY Incyte NBIX Neurocrine Biosciences PRLD Prelude Therapeutics PTCT PTC Therapeutics RARE Ultragenyx RYTM Rhythm Pharmaceuticals SAGE Sage Therapeutic ASND Ascendis Pharma AS CRTX Cortexyme ORPH Orphazyme A/S SRPT Sarepta Therapeutics BCRX BioCryst Pharmaceuticals PRTA Prothena plc SRZN Surrozen TBPH Theravance Biopharma ADCT ADC Therapeutics SA FATE Fate Therapeutics ADMS Adamas Pharmaceuticals AKUS Akouos ARGX argenx NV ADR CLVS Clovis Oncology CYT Cyteir Therapeutics ETN Eaton PLC KALA Kala Pharmaceuticals MCRB Seres Therapeutics SGEN Seagen SQZ Sqz Biotechnologies Co ZGNX Zogenix ANNX Annexon ARVN Arvinas PRAX Praxis Precision Medicines ACHL Achilles Therapeutics PLC ADR APLS Apellis Pharmaceuticals CERE Cerevel Therapeutics Holdings PHVS Pharvaris BV FDMT 4D Molecular Therapeutics INZY Inozyme Pharma MRUS Merus BV PEPG PepGen Ltd IMMU Immunomedics DNLI Denali Therapeutics OCUL Ocular Therapeutix PRNB Principia Biopharma STRO Sutro Biopharma KALV Kalvista Pharmaceuticals CORT Corcept Therapeutics SRRK Scholar Rock Holding Corp TCP TC PipeLines LP KYMR Kymera Therapeutics REGN Regeneron Pharmaceuticals TSHA Taysha Gene Therapies VRTX Vertex Pharmaceuticals

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Hold Since 16-May-2025

$21

$3.89 (22.74%)

$25

4 days ago
(18-Nov-2026)

Hold Since 07-Mar-2025

$24

$6.89 (40.27%)

$28

9 days ago
(13-Nov-2026)

24/31 (77.42%)

$5.25 (28.00%)

206

Buy Since 22-Jun-2022

$38

$20.89 (122.09%)

$36

16 days ago
(06-Nov-2026)

13/23 (56.52%)

$16.77 (78.99%)

197

Buy Since 23-Jun-2025

$38

$20.89 (122.09%)

$36

17 days ago
(05-Nov-2026)

1/11 (9.09%)

$16.76 (78.91%)

173

Buy Since 28-Feb-2024

$35

$17.89 (104.56%)

$35

1 months 3 days ago
(19-Oct-2026)

9/17 (52.94%)

$15.2 (76.77%)

393

Show more analysts

Stocks Tazeen Ahmad covered previously. Scores are shown for active stocks only.

BCAX Bicara Therapeutics BLTE Belite Bio ADR ETNB 89bio OR Osisko Gold Ro PRVL Prevail Therapeutics PYXS Pyxis Oncology RNA Avidity Biosciences SG Sweetgreen

Please expand the browser size to see the chart

Which stock is Tazeen Ahmad most bullish on?

Potential upside of $262.18 has been obtained for ALNY (ALNYLAM PHARMACEUTICALS)

Which stock is Tazeen Ahmad most reserved on?

Potential downside of $6.28 has been obtained for TSHA (TAYSHA GENE THERAPIES)

What Year was the first public recommendation made by Tazeen Ahmad?

On 2009
✖

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?